Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. 2014

Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia.

For many respiratory infections caused by multidrug-resistant Gram-negative bacteria, colistin is the only effective antibiotic despite its nephrotoxicity. A novel inhaled combination formulation of colistin with a synergistic antimicrobial component of rifampicin was prepared via co-spray drying, aiming to deliver the drug directly to the respiratory tract and minimize drug resistance and adverse effects. Synergistic antibacterial activity against Acinetobacter baumannii was demonstrated for the combination formulation with high emitted doses (96%) and fine particle fraction total (FPFtotal; 92%). Storage of the spray-dried colistin alone formulation in the elevated relative humidity (RH) of 75% resulted in a substantial deterioration in the aerosolization performance because the amorphous colistin powders absorbed significant amount of water up to 30% by weight. In contrast, the FPFtotal values of the combination formulation stored at various RH were unchanged, which was similar to the aerosolization behavior of the spray-dried rifampicin-alone formulation. Advanced surface chemistry measurements by XPS and ToF-SIMS demonstrated a dominance of rifampicin on the combination particle surfaces, which contributed to the moisture protection at the elevated RH. This study shows a novel inhalable powder formulation of antibiotic combination with the combined beneficial properties of synergistic antibacterial activity, high aerosolization efficiency, and moisture protection.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D011208 Powders Substances made up of an aggregation of small particles, as that obtained by grinding or trituration of a solid drug. In pharmacy it is a form in which substances are administered. (From Dorland, 28th ed) Powder
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D003091 Colistin Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. Polymyxin E,Colimycin,Colisticin,Colistin Sulfate,Coly-Mycin,Totazina,Sulfate, Colistin
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006813 Humidity A measure of the amount of WATER VAPOR in the air. Humidities
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
October 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
January 2019, Antimicrobial agents and chemotherapy,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
October 2013, Journal of pharmaceutical sciences,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
May 2009, Pharmaceutical research,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
September 2018, Molecular pharmaceutics,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
August 2007, The Journal of antimicrobial chemotherapy,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
September 1971, Arzneimittel-Forschung,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
August 2014, Journal of chemotherapy (Florence, Italy),
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
June 2013, Acta microbiologica et immunologica Hungarica,
Qi Tony Zhou, and Thomas Gengenbach, and John A Denman, and Heidi H Yu, and Jian Li, and Hak Kim Chan
April 2016, Journal of pharmaceutical sciences,
Copied contents to your clipboard!